Published On: Wed, Oct 19th, 2016

Analyst Coverage: Seres Health, Inc. (NASDAQ:MCRB)


Recently stock market analysts have updated their consensus ratings on shares of Seres Health, Inc. (NASDAQ:MCRB).

Most recent broker ratings

08/12/2016 – Seres Health, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 23 price target on the stock.

08/01/2016 – Seres Health, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 15 price target on the stock.

08/01/2016 – Seres Health, Inc. was downgraded to “neutral” by analysts at Bank of America Merrill Lynch.

07/29/2016 – Seres Health, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 12 price target on the stock.

06/06/2016 – Cowen began new coverage on Seres Health, Inc. giving the company a “outperform” rating.

03/03/2016 – Guggenheim began new coverage on Seres Health, Inc. giving the company a “buy” rating. They now have a USD 41 price target on the stock.

11/10/2015 – Seres Health, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity.

07/21/2015 – Goldman Sachs began new coverage on Seres Health, Inc. giving the company a “neutral” rating. They now have a USD 36 price target on the stock.

Seres Health, Inc. has a 50 day moving average of 11.87 and a 200 day moving average of 22.38. The stock’s market capitalization is 470.00M, it has a 52-week low of 8.05 and a 52-week high of 44.51.

The share price of the company (NASDAQ:MCRB) was up +2.82%, with a high of 11.76during the day and the volume of Seres Health, Inc. shares traded was 226384.

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases.